News and Announcements
Cellmid Limited – Midkine Antibodies Effective in Cancer
- Published October 04, 2013 10:51AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
- Anti-midkine antibodies reduce tumour growth and spread
- Anti-angiogenic mechanism of action also evident
- Final studies in the programme to determine Cellmid’s clinical direction
SYDNEY, Thursday, 03 October 2013: Cellmid Limited (ASX: CDY) is pleased to advise that it has now completed its several cancer xenograft efficacy and mechanism of action studies using the company’s lead anti-midkine (MK) antibody with compelling results.
The MK antibody treatment slowed primary tumour growth, reduced cancer spread (metastasis) and slowed the formation of new blood vessels (angiogenesis) in different tumour types. These findings complete the Company’s extensive preclinical programme to determine clinical direction for its MK antibodies.
The findings of the current studies have been consistent with the results published recently by an independent research group (Hao, et al. Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer (2013) http://www.ncbi.nlm.nih.gov/pubmed/23976985)and add to the growing evidence of midkine’s importance in cancer.
To read the full ASX Release please click on the document below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
